Paxlovid for hospitalized COVID-19 patients with chronic kidney disease

BACKGROUND: COVID-19 causes significant mortality during the recent pandemic. Data regarding the effectiveness of Paxlovid on COVID-19 patients with chronic kidney disease (CKD, eGFR <90 ml/min) are limited. METHODS: A retrospective cohort study was performed on the clinical data of the hospitali...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Hong, Yan, Jiayi, Liu, Shang, Li, Ping, Ding, Li, Zhan, Yaping, Lu, Jiayue, Li, Zhenyuan, Zhu, Mingli, Gao, Yuan, Gong, XingRong, Ban, Haiqun, Gu, Leyi, Zhou, Weibin, Wang, Jieying, Mou, Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290896/
https://www.ncbi.nlm.nih.gov/pubmed/37369283
http://dx.doi.org/10.1016/j.antiviral.2023.105659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290896/
https://www.ncbi.nlm.nih.gov/pubmed/37369283
http://dx.doi.org/10.1016/j.antiviral.2023.105659

Ejemplares similares